At the American Diabetes Association's 78th Annual Scientific Sessions, Robert Gabbay, MD, PhD, the chief medical officer and senior vice president of the Joslin Diabetes Center, spoke with MD Mag about the controversies and debates surrounding sodium-glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists—2 classes of efficacious, but rather underused, medications.

свернуть